• Publications
  • Influence
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
These revisions evolved as the guidelines were used in a systematic fashion in large clinical trials and with the experience following the use of newer, more effective agents, such as fludarabine.
Acute lymphoblastic leukemia.
These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment approaches based on the Philadelphia chromosome status and age, assessment of minimal residual disease, and supportive care considerations.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
  • J. Byrd, Jennifer R Brown, +32 authors P. Hillmen
  • Medicine
    The New England journal of medicine
  • 11 July 2014
Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.
The biology of chronic myeloid leukemia.
Although heterogeneous, CML is the best-characterized leukemia at a molecular level, and studies in recent years have helped to define further.
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML, and common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes.
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib, which is effective in Philadelphia chromosome-positive leukemias but relapse occurs.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
The combination of idelalisib and rituximab, as compared with placebo and r ituximabs, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy.
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Single-agent blinatumomab showed antileukaemia activity in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia characterised by negative prognostic factors.
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Hyper-CVAD therapy is superior to previous regimens and should be compared with established regimens in adult ALL, and a smaller percentage had more than 5% day 14 blasts and better survival.